Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4988
Gene Symbol: OPRM1
OPRM1
0.400 Biomarker group BEFREE To deal successfully with the opioid crisis, we need to discover novel analgesics whose mechanisms do not involve the mu opioid receptor but that have high analgesic potency and low risk of adverse effects, particularly no abuse liability.The question is how to achieve this. 31399256 2020
Entrez Id: 4988
Gene Symbol: OPRM1
OPRM1
0.400 Biomarker group BEFREE Future studies with ICSS could help (a) to clarify mechanisms that increase MOR agonist abuse potential during early opioid exposure or during chronic exposure leading to dependence, (b) to evaluate novel opioids either developed as candidate analgesics with reduced abuse potential or identified as designer opioids being synthesized and distributed for illicit use, and (c) to test candidate pharmacotherapies for treatment of opioid abuse in non-dependent and dependent subjects. 30391425 2019
Entrez Id: 4988
Gene Symbol: OPRM1
OPRM1
0.400 Biomarker group BEFREE The combination of MOR agonists with non-MOR agonists may increase the analgesic potency of MOR agonists, reduce the development of tolerance and dependence, reduce the diversion and abuse, overdose, and reduce other clinically significant side effects associated with prolonged opioid use such as constipation. 31029588 2019
Entrez Id: 4988
Gene Symbol: OPRM1
OPRM1
0.400 GeneticVariation group BEFREE The OPRM1 rs1799971" genes_norm="4988">A118G single nucleotide polymorphism (SNP rs1799971) gene variant encoding the rs1799971" genes_norm="4988">N40D µ-opioid receptor (MOR) has been associated with dependence on opiates and other drugs of abuse but its mechanism is unknown. 31481756 2019
Entrez Id: 4988
Gene Symbol: OPRM1
OPRM1
0.400 Biomarker group BEFREE This study assessed the impact of one synthetic cannabinoid, JWH-018, on the effects of two μ opioid receptor agonists using two procedures that address different aspects of abuse. 31295696 2019
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.400 Biomarker group BEFREE Repeated exposure to mixed-action DAT≈SERT substrates such as mephedrone can result in increased abuse potential due to sustained expression of DAT-mediated abuse-related effects and tolerance to SERT-mediated abuse-limiting effects. 30232529 2019
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.400 Biomarker group BEFREE However, under an additive model there was also an interaction between sexual and physical abuse considered independently and 5-HTTLPR, and no interaction with traumatic life events. 27701012 2017
Entrez Id: 4988
Gene Symbol: OPRM1
OPRM1
0.400 Biomarker group BEFREE The δ opioid receptor (δR) is a promising alternate target for pain management because δR agonists show decreased abuse potential compared with current opioid analgesics that target the μ opioid receptor. 28264976 2017
Entrez Id: 4988
Gene Symbol: OPRM1
OPRM1
0.400 Biomarker group CTD_human Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators. 27192616 2016
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.400 GeneticVariation group BEFREE Our study included 2679 participants.Those with both the 5-HTTLPR s allele and the BDNF Met allele showed the highest risk of MD if they had previously experienced emotional (z = 2.08, p = 0.037), sexual (z = 2.19, p = 0.029) or any kind of childhood abuse (z = 2.37, p = 0.018). 25510949 2015
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.400 GeneticVariation group BEFREE The SS genotype of the serotonin transporter gene (5-HTTLPR) was associated with high levels of impulsivity when the subjects reported emotional abuse [odds ratio (OR) 5.55, 95% confidence interval (CI) 1.75-17.5] or physical abuse (OR 5.03, 95% CI 1.50-16.9) in their childhood. 25065374 2014
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 AlteredExpression group BEFREE Similarly, women with a BSD who reported a history of childhood sexual abuse showed a trend-level elevation of DRD2 methylation compared to our NED group. 24157248 2014
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.400 Biomarker group BEFREE In multivariable logistic regression analysis, an interaction between abuse and 5-HTTLPR group was significantly associated with non-change status, along with partner communication frequency scores at follow-up. 23479192 2014
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 GeneticVariation group BEFREE We hypothesize that dopamine D2 receptor (DRD2) gene Taq1 A2 allele is associated with a subtype of non-SUD schizophrenics and as such may act as a putative protective agent against the development of addiction to alcohol or other drugs of abuse. 24636783 2014
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.400 GeneticVariation group BEFREE We hypothesize that functional polymorphisms (TPH2: rs7305115, 5-HTTLPR and rs25531) within both genes contribute to the risk of depressive disorders after childhood abuse in adult life. 25214390 2014
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.400 GeneticVariation group BEFREE Significant four-way interactions were found for BDNF Val66Met × 5-HTTLPR×MAOA-uVNTR × family conflicts and for BDNF Val66Met × 5-HTTLPR×MAOA-uVNTR × sexual abuse. 25522433 2014
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.400 GeneticVariation group BEFREE Consequently, we examined how serotonin transporter (5-HTTLPR) polymorphisms, monoamine oxidase-A (MAO-A) variants, and childhood abuse measured with the Childhood Trauma Questionnaire relate to dimensions of psychopathy in a forensic sample of 237 men with elevated levels of environmental adversity. 22985017 2013
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.400 GeneticVariation group BEFREE For the four MDD outcome measures, we examined the direct effects of 5-HTTLPR/rs25531-haplotypes, five environmental factors (lifetime and recent stressful life-events, sexual abuse, low educational attainment, and childhood trauma) and their interaction in logistic regression models. 23021380 2013
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 Biomarker group BEFREE Dopamine (DA) neurotransmission through D2 receptors (DRD2) has been implicated in the regulation of reward processing, cognition and the effects of drugs of abuse, and also has significant effects in responses to stressors and salient aversive stimuli. 22424959 2013
Entrez Id: 4988
Gene Symbol: OPRM1
OPRM1
0.400 Biomarker group BEFREE The μ-opioid receptor (MOR) binds exogenous and endogenous opioids and is known to mediate the rewarding effects of drugs of abuse. 23454283 2013
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.400 Biomarker group BEFREE The meta-analyses support the associations of 5-HTTLPR with alcohol, heroin, cocaine, and methamphetamine dependence and abuse (eg, the smallest P-values were 0.0058 with odds ratio (OR)=0.54 (0.35, 0.84); 0.0024 with OR=0.77 (0.66, 0.91); 0.018 with OR=1.38 (1.06, 1.81); and 0.028 with OR=0.46 (0.23, 0.92) for alcohol, heroin, cocaine, and methamphetamine dependence/abuse, respectively). 23518607 2013
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.400 GeneticVariation group BEFREE Significant interactions with additive and recessive 5-HTTLPR genetic models were found for overall severity of maltreatment, sexual abuse and to a lesser degree for physical neglect, but not other maltreatment types. 22840631 2013
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.400 Biomarker group BEFREE The interaction effect of the 5-HTTLPR and the past sexual abuse was also observed on drive for thinness. 22018958 2012
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 GeneticVariation group BEFREE Sensation Seeking was elevated in carriers of the low-function allele of the DRD2 Taq1A polymorphism who also reported childhood sexual abuse, relative to that in individuals showing other combinations of alleles and abuse exposures. 22733030 2012
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.400 GeneticVariation group BEFREE Our results point to a gene-gene-environment interaction that relevantly impacts on the role of the s/s genotype of the 5-HTTLPR in childhood abuse: Depending on the BDNF background (Val/Val versus Met allele) the s/s genotype showed either protective or risk properties with regard to depressive symptoms. 21996278 2012